EUVIMEDEUVIMED entdecken
VergleichsstudieEvaluationsstudieOpen Access · CC BY 4.0

Comparative Evaluation of HPV PLUS ELITe MGB® and Allplex™ HPV HR Assays for High‐Risk Human Papillomavirus Genotyping in Cervical Samples

Sarah Mafi iD, Julie Delpont, Amandine Bigot, Sébastien Hantz

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.70954 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Sarah Mafi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacteriology, Virology and Hygiene, Limoges University Hospital, Limoges, France. Hauptthemen laut MEDLINE: Papillomavirus Infections, Cervix Uteri, Papillomaviridae, Genotyping Techniques. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To compare the performance of the HPV PLUS ELITe MGB® (ELITechGroup) and Allplex™ HPV HR (Seegene) assays for the detection and genotyping of high‐risk HPV (HR‐HPV) in cervical samples. HPV typing results using both techniques were obtained for 491/500 cervical samples. The ELITe assay provides individual detection of HPV16, 18, 31 and 45, and pooled detection of other HR‐HPV into HR1 (33/52/58) and HR2 (35/39/51/56/59/66/68), whereas the Allplex™ assay provides individual detection of all HR‐HPV types. Cytological data were available for 283 samples. Concordance, percent agreements, and kappa coefficient were calculated. Ct values, discordances, and associations with cytology were analyzed. Overall agreement was 88.6% ( κ = 0.77, substantial). HPV DNA was detected in 40.5% (199/491) of samples with the ELITe assay and 47.9% (235/491) with the Allplex™ assay. The Allplex™ assay showed significantly higher detection than the ELITe assay for HPV16 (50 vs. 36), HPV18 (37 vs. 26), and HR1 genotypes (66 vs. 48, particularly HPV52). Most ELITe − /Allplex+ cases occurred in NILM and ASCUS samples (58% showing Ct ≤ 35), but with no significant difference regardless of cytology. The Allplex™ assay demonstrated higher analytical sensitivity for clinically relevant genotypes. This increased detection could reflect earlier identification before lesion onset or, conversely, detection of transient infections of uncertain clinical relevance, underscoring the need to balance analytical performance with clinical utility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsCervix UteriPapillomaviridaeGenotyping TechniquesHuman Papillomavirus VirusesMolecular Diagnostic TechniquesHumansFemaleGenotypeDNA, ViralAdultSensitivity and SpecificityMiddle AgedYoung Adult

Stichwörter der Autor:innen

Allplex™ HPV28ELITe MGB®HPV genotypingcervical samplescomparative studyhigh‐risk HPV

Substanzen

DNA, Viral

Autor:innen und Institutionen

  • Department of Bacteriology, Virology and Hygiene, Limoges University Hospital, Limoges, France.
  • University of Limoges, INSERM, RESINFIT, Limoges, France.

ORCID-Profile: Sarah Mafi

Zitieren

APA

Mafi, S., Delpont, J., Bigot, A., & Hantz, S. (2026). Comparative Evaluation of HPV PLUS ELITe MGB® and Allplex™ HPV HR Assays for High‐Risk Human Papillomavirus Genotyping in Cervical Samples. Journal of Medical Virology. https://doi.org/10.1002/jmv.70954

Vancouver

Mafi S, Delpont J, Bigot A, Hantz S. Comparative Evaluation of HPV PLUS ELITe MGB® and Allplex™ HPV HR Assays for High‐Risk Human Papillomavirus Genotyping in Cervical Samples. Journal of Medical Virology. 2026. doi:10.1002/jmv.70954

BibTeX
@article{Mafi2026,
  author = {Mafi, Sarah and Delpont, Julie and Bigot, Amandine and Hantz, Sébastien},
  title = {Comparative Evaluation of HPV PLUS ELITe MGB® and Allplex™ HPV HR Assays for High‐Risk Human Papillomavirus Genotyping in Cervical Samples},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.70954}
}
Kostenlos starten →